Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FUTURE-SUPER: Umbrella Trial for Metastatic TNBC
NCT04395989Phase 2Active, not recruiting
- Sponsor
- Fudan University
- Start
- Jul 2020
- Primary completion
- May 2023
- Modality
- Fragment-Derived Small Molecules, Immune Checkpoint Inhibitors, Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pyrotinib, everolimus, camrelizumab, famitinib and bevacizumab in triple-negative breast cancer (TNBC) (10 arms), sponsored by Fudan University. Primary endpoint: Progression Free Survival at 3 years. Started Jul 2020; status: active, not recruiting.
02
Drugs
pyrotinibeverolimuscamrelizumabfamitinibbevacizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04395989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04395989.